{"id":41312,"date":"2019-03-08T08:48:41","date_gmt":"2019-03-08T13:48:41","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=41312"},"modified":"2019-03-08T08:48:45","modified_gmt":"2019-03-08T13:48:45","slug":"2019-to-be-a-year-of-critical-milestones-for-q-biomed-qbio","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/2019-to-be-a-year-of-critical-milestones-for-q-biomed-qbio-41312","title":{"rendered":"2019 To Be a Year of Critical Milestones for Q Biomed (QBIO)"},"content":{"rendered":"\n<br>\n\n\n\nEvery publicly traded biotechnology company lives through a series of binary events and inflection points. It\u2019s simply the nature of the fickle investor beast. Sometimes, a series of these milestone events meet in a perfect storm of possibility. That\u2019s what 2019 is shaping up to be for Q BioMed (OTCQB: QBIO), a company that just may have a better mousetrap to accelerate the monetization of biomedical technologies.\n\n\n\nQ BioMed has a depth and breadth of platform that is rarely found among such young biotechnology companies. Founded less than six years ago, the company is focused on licensing, acquiring and providing strategic resources to life sciences and healthcare companies. Q BioMed\u2019s strategy has been to mitigate risk by acquiring multiple assets over time and across a broad spectrum of healthcare related products, companies and sectors. The company aims to develop these assets to provide shareholder returns via organic growth, revenue production, out-licensing, sale or spinoff of new public companies.\n\n\n\nThe company has four distinct programs across the spectrum of development stages. Q BioMed anticipates making tangible progress in all programs this year, with demonstrable milestones expected to be achieved in each program.\n\n\n\n<strong>Metastron&#x2122; (Strontium Chloride 89) -FDA-approved<\/strong>\n\n\n\nMetastron is the company\u2019s non-opioid pain reliever for palliative treatment of bone pain from cancer metastases.\n\n\n\n\u00b7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The drug is already FDA-approved, and the company is awaiting FDA review of a new cGMP manufacturing facility.\n\n\n\n\u00b7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Q BioMed expects to generate revenue from Metastron in the first half of 2019\n\n\n\n\u00b7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A Phase 4 post-marketing study for an expanded therapeutic label is expected to begin in the fourth quarter of 2019\n\n\n\n&nbsp;<strong>QBM-001 for Rare Pediatric Non-Verbal Disorder\u2014an Autism Spectrum Disorder<\/strong>\n\n\n\nQBM-001 acts as a regulator of faulty membrane channels in the brain that are known to cause migraines and\/or seizures. Regulation of these channels would allow QBM-001 to potentially alleviate non-verbal disorder and allow toddlers to actively develop language and avoid life-long speech and intellectual impairment.\n\n\n\n\u00b7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The program was featured in the February issue of&nbsp;<em>DDNews<\/em>, a monthly newspaper dedicated to the news of technology and business in the pharmaceutical and biotechnology industries, whose web usage generates over 4.6 million downloaded pages a year.\n\n\n\n\u00b7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pre-IND Filing and0 Orphan Drug Filing are expected with the FDA in the first half of 2019\n\n\n\n\u00b7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A 5-year pivotal clinical trial is expected to begin in the second half of 2019\n\n\n\n<strong>Uttroside-B Chemotherapy for Liver Cancer<\/strong>\n\n\n\nUttroside-B appears to affect pro survival signaling and cell death in a variety of liver cancer cell types.&nbsp;\n\n\n\n\u00b7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Provisional patent has been filed, and molecule synthesis was completed in December 2018\n\n\n\n\u00b7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Completing pre-clinical work now. Proof of concept studies will be done in the first half of 2019\n\n\n\n\u00b7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We expect to file an IND in the third quarter of 2019\n\n\n\n<strong>MAN-01 for Primary Open-Angle Glaucoma<\/strong>\n\n\n\nMAN-01 is a topical eye drop for glaucoma, whose novel mechanism of action targets Schlemm\u2019s Canal which is responsible for 70%-90% of fluid drainage in the eye.\n\n\n\n\u00b7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Completing molecule optimization for eye drop formulation\n\n\n\n\u00b7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Initiating pre-IND studies in the first half of 2019\n\n\n\n\u00b7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We expect to file an IND in 2019\n\n\n\n\u00b7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have formalized additional indications including acute kidney injury, cardiovascular disease and infectious disease.\n\n\n\nQ BioMed stock has rebounded well from its $0.90 lows at Christmastime and is currently at $1.66 as of afternoon trading on March 7<sup>th<\/sup>. &nbsp;The current market cap of $24 million seems very light for a company that\u2019s anticipated to hit milestones across its portfolio in 2019.&nbsp;\n","protected":false},"excerpt":{"rendered":"<p>Every publicly traded biotechnology company lives through a series of binary events and inflection points. It\u2019s simply the nature of the fickle investor beast. Sometimes, [&hellip;]<\/p>\n","protected":false},"author":13,"featured_media":41090,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[2236],"tags":[13481,13472],"stock_ticker":[],"class_list":["post-41312","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business","tag-otcmktsqbio","tag-qbio","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>2019 To Be a Year of Critical Milestones for Q Biomed (QBIO) - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/2019-to-be-a-year-of-critical-milestones-for-q-biomed-qbio-41312\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"2019 To Be a Year of Critical Milestones for Q Biomed (QBIO) - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Every publicly traded biotechnology company lives through a series of binary events and inflection points. It\u2019s simply the nature of the fickle investor beast. Sometimes, [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/2019-to-be-a-year-of-critical-milestones-for-q-biomed-qbio-41312\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-03-08T13:48:41+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2019-03-08T13:48:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2018\/08\/Enecuum-Partners-With-iCapital.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"820\" \/>\n\t<meta property=\"og:image:height\" content=\"500\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Lisa Ray\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Lisa Ray\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/2019-to-be-a-year-of-critical-milestones-for-q-biomed-qbio-41312#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/2019-to-be-a-year-of-critical-milestones-for-q-biomed-qbio-41312\"},\"author\":{\"name\":\"Lisa Ray\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/c58aa72f5e3994c817e3654937496b1c\"},\"headline\":\"2019 To Be a Year of Critical Milestones for Q Biomed (QBIO)\",\"datePublished\":\"2019-03-08T13:48:41+00:00\",\"dateModified\":\"2019-03-08T13:48:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/2019-to-be-a-year-of-critical-milestones-for-q-biomed-qbio-41312\"},\"wordCount\":696,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/2019-to-be-a-year-of-critical-milestones-for-q-biomed-qbio-41312#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2018\/08\/Enecuum-Partners-With-iCapital.jpg\",\"keywords\":[\"OTCMKTS:QBIO\",\"QBIO\"],\"articleSection\":[\"Business\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/2019-to-be-a-year-of-critical-milestones-for-q-biomed-qbio-41312#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/2019-to-be-a-year-of-critical-milestones-for-q-biomed-qbio-41312\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/2019-to-be-a-year-of-critical-milestones-for-q-biomed-qbio-41312\",\"name\":\"2019 To Be a Year of Critical Milestones for Q Biomed (QBIO) - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/2019-to-be-a-year-of-critical-milestones-for-q-biomed-qbio-41312#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/2019-to-be-a-year-of-critical-milestones-for-q-biomed-qbio-41312#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2018\/08\/Enecuum-Partners-With-iCapital.jpg\",\"datePublished\":\"2019-03-08T13:48:41+00:00\",\"dateModified\":\"2019-03-08T13:48:45+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/2019-to-be-a-year-of-critical-milestones-for-q-biomed-qbio-41312#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/2019-to-be-a-year-of-critical-milestones-for-q-biomed-qbio-41312\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/2019-to-be-a-year-of-critical-milestones-for-q-biomed-qbio-41312#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2018\/08\/Enecuum-Partners-With-iCapital.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2018\/08\/Enecuum-Partners-With-iCapital.jpg\",\"width\":820,\"height\":500},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/2019-to-be-a-year-of-critical-milestones-for-q-biomed-qbio-41312#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"2019 To Be a Year of Critical Milestones for Q Biomed (QBIO)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/c58aa72f5e3994c817e3654937496b1c\",\"name\":\"Lisa Ray\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/2b2b9819092dcc9a125cbbf7b3645b09.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/2b2b9819092dcc9a125cbbf7b3645b09.png\",\"caption\":\"Lisa Ray\"},\"description\":\"Lisa has a Bachelor of Arts in journalism from Purdue University and 3 years of experience in the publishing field.\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/linsay-thomas\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"2019 To Be a Year of Critical Milestones for Q Biomed (QBIO) - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/2019-to-be-a-year-of-critical-milestones-for-q-biomed-qbio-41312","og_locale":"en_US","og_type":"article","og_title":"2019 To Be a Year of Critical Milestones for Q Biomed (QBIO) - Wall Street PR","og_description":"Every publicly traded biotechnology company lives through a series of binary events and inflection points. It\u2019s simply the nature of the fickle investor beast. Sometimes, [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/2019-to-be-a-year-of-critical-milestones-for-q-biomed-qbio-41312","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2019-03-08T13:48:41+00:00","article_modified_time":"2019-03-08T13:48:45+00:00","og_image":[{"width":820,"height":500,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2018\/08\/Enecuum-Partners-With-iCapital.jpg","type":"image\/jpeg"}],"author":"Lisa Ray","twitter_misc":{"Written by":"Lisa Ray","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/2019-to-be-a-year-of-critical-milestones-for-q-biomed-qbio-41312#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/2019-to-be-a-year-of-critical-milestones-for-q-biomed-qbio-41312"},"author":{"name":"Lisa Ray","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/c58aa72f5e3994c817e3654937496b1c"},"headline":"2019 To Be a Year of Critical Milestones for Q Biomed (QBIO)","datePublished":"2019-03-08T13:48:41+00:00","dateModified":"2019-03-08T13:48:45+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/2019-to-be-a-year-of-critical-milestones-for-q-biomed-qbio-41312"},"wordCount":696,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/2019-to-be-a-year-of-critical-milestones-for-q-biomed-qbio-41312#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2018\/08\/Enecuum-Partners-With-iCapital.jpg","keywords":["OTCMKTS:QBIO","QBIO"],"articleSection":["Business"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/2019-to-be-a-year-of-critical-milestones-for-q-biomed-qbio-41312#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/2019-to-be-a-year-of-critical-milestones-for-q-biomed-qbio-41312","url":"https:\/\/cablemanpro.com\/wallstreetpr\/2019-to-be-a-year-of-critical-milestones-for-q-biomed-qbio-41312","name":"2019 To Be a Year of Critical Milestones for Q Biomed (QBIO) - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/2019-to-be-a-year-of-critical-milestones-for-q-biomed-qbio-41312#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/2019-to-be-a-year-of-critical-milestones-for-q-biomed-qbio-41312#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2018\/08\/Enecuum-Partners-With-iCapital.jpg","datePublished":"2019-03-08T13:48:41+00:00","dateModified":"2019-03-08T13:48:45+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/2019-to-be-a-year-of-critical-milestones-for-q-biomed-qbio-41312#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/2019-to-be-a-year-of-critical-milestones-for-q-biomed-qbio-41312"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/2019-to-be-a-year-of-critical-milestones-for-q-biomed-qbio-41312#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2018\/08\/Enecuum-Partners-With-iCapital.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2018\/08\/Enecuum-Partners-With-iCapital.jpg","width":820,"height":500},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/2019-to-be-a-year-of-critical-milestones-for-q-biomed-qbio-41312#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"2019 To Be a Year of Critical Milestones for Q Biomed (QBIO)"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/c58aa72f5e3994c817e3654937496b1c","name":"Lisa Ray","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/2b2b9819092dcc9a125cbbf7b3645b09.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/2b2b9819092dcc9a125cbbf7b3645b09.png","caption":"Lisa Ray"},"description":"Lisa has a Bachelor of Arts in journalism from Purdue University and 3 years of experience in the publishing field.","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/linsay-thomas"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/41312","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=41312"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/41312\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/41090"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=41312"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=41312"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=41312"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=41312"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}